Opportunity Information: Apply for RFA AI 14 066
Apply for RFA AI 14 066
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Non Traditional Therapeutics that Limit Antibacterial Resistance (R21/R33)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Nov 14, 2014 and posted on Nov 14, 2014.
- Applicants must submit their applications by Feb 23, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Public housing authorities/Indian housing authorities Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Private institutions of higher education City or township governments Special district governments County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Small businesses Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity "Non Traditional Therapeutics that Limit Antibacterial Resistance (R21/R33)" (Funding Opportunity Number RFA-AI-14-066) is a National Institutes of Health (NIH) discretionary grant aimed at accelerating early stage translational research that could lead to new ways of treating infections without relying on conventional antibiotics. The central idea is to support discovery and early development of "non-traditional" therapeutic approaches that can either bypass the mechanisms that drive antibiotic resistance or reduce the selective pressure that typically causes bacteria to evolve resistance. In practical terms, the announcement is framed around the growing public health threat of antibacterial resistance and looks for projects that can produce credible alternative treatment modalities for infected patients, moving beyond standard small-molecule antibiotics.
This opportunity uses an R21/R33 funding structure, which is commonly designed to help teams move from an exploratory, proof-of-concept phase into a more advanced development phase if early milestones are met. The R21 portion generally fits projects that are still establishing feasibility, generating key preliminary data, or validating a novel concept, while the R33 portion is intended to support the next step of development and translation once the approach looks promising. In the context of this announcement, that means NIH is looking for work that does not stop at basic discovery, but is positioned to progress toward tangible therapeutic candidates or intervention strategies that could ultimately be tested and used clinically to treat infections in ways that help limit resistance.
The activity category is Health, and the funding is associated with CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research, reflecting the programmatic focus on infectious disease and microbiology. There is no cost sharing or matching requirement, so applicants are not required to contribute non-federal funds as a condition of the award.
Eligibility is broad and includes many types of organizations. Eligible applicants include federal, state, county, city or township governments, and special district governments, along with public housing authorities/Indian housing authorities and independent school districts. Academic applicants can include public and state-controlled institutions of higher education as well as private institutions of higher education. The announcement also allows nonprofit organizations both with and without 501(c)(3) IRS status (with the latter category explicitly allowed when not an institution of higher education). For-profit organizations are eligible as well, including small businesses and other for-profit entities (excluding the limitation to small business that appears in some other programs). The opportunity also explicitly includes Native American tribal governments (federally recognized) and Native American tribal organizations that are not federally recognized, as well as tribally controlled colleges and universities (TCCUs). It further lists several mission-focused institutional categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and eligible agencies of the federal government. Notably, the FOA allows non-U.S. participation: foreign organizations and foreign institutions may apply, non-domestic components of U.S. organizations are eligible, and foreign components (as defined by NIH policy) are allowed.
From a timeline perspective, the announcement was posted and created on November 14, 2014, with an original and current closing date of February 23, 2015. The archive date is March 26, 2015, meaning it is no longer an active open solicitation, but it remains a useful reference for the kinds of research NIH has sought to stimulate in this area. The official announcement was hosted by NIH and is referenced through the grants.nih.gov RFA page (http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-066.html), and the contact listed for access or linking issues is the NIH Office of Extramural Research (OER) Webmaster (FBOWebmaster@OD.NIH.GOV).
Overall, the opportunity is best understood as NIH support for translationally oriented projects that can lead to alternatives to traditional antibiotics, specifically with an eye toward reducing the clinical and societal impact of antimicrobial resistance. It emphasizes innovation in treatment strategies for infections and encourages applicants from a wide range of institutional types, including international entities, reflecting both the complexity of resistance and the global scale of the problem.
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled Non Traditional Therapeutics that Limit Antibacterial Resistance (R21/R33).
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-AI-14-066.
Which agency is offering this funding?
This is a National Institutes of Health (NIH) discretionary grant opportunity.
What is the main purpose of this funding opportunity?
The purpose is to accelerate early stage translational research that could lead to new ways of treating infections without relying on conventional antibiotics, with an emphasis on approaches that help limit or avoid antibacterial resistance.
What problem area is this FOA trying to address?
The FOA is framed around the growing public health threat of antibacterial (antimicrobial) resistance and seeks credible alternative treatment modalities that could reduce the clinical and societal impact of resistance.
What does "non-traditional therapeutics" mean in this announcement?
In this announcement, "non-traditional" refers to therapeutic approaches that bypass mechanisms that drive antibiotic resistance or reduce the selective pressure that commonly causes bacteria to evolve resistance, rather than relying on standard small-molecule antibiotics.
Does this FOA focus on basic research or translational research?
The emphasis is on translationally oriented work. While early discovery may be part of a project, NIH is looking for efforts positioned to progress toward tangible therapeutic candidates or intervention strategies that could ultimately be tested and used clinically.
What grant mechanism does this opportunity use?
This opportunity uses an R21/R33 funding structure.
What is the R21 phase intended to support?
The R21 portion generally fits projects that are still establishing feasibility, generating key preliminary data, or validating a novel concept (proof-of-concept / exploratory work).
What is the R33 phase intended to support?
The R33 portion is intended to support the next step of development and translation once the approach looks promising.
How does a project move from the R21 phase to the R33 phase?
The FOA describes the R21/R33 structure as supporting progression into the R33 phase if early milestones are met.
What is the activity category for this opportunity?
The activity category is Health.
Which CFDA numbers are associated with this opportunity?
The associated CFDA numbers are 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research).
Is cost sharing or matching required?
No. The opportunity specifies no cost sharing or matching requirement, so applicants are not required to contribute non-federal funds as a condition of the award.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include many types of U.S. government entities, education institutions, nonprofits, for-profits, tribal entities, and other organizational categories explicitly listed in the announcement.
Are U.S. government entities eligible applicants?
Yes. Eligible applicants include federal, state, county, city or township governments and special district governments, as well as eligible agencies of the federal government.
Are public housing authorities eligible?
Yes. The opportunity includes public housing authorities/Indian housing authorities as eligible applicants.
Are independent school districts eligible?
Yes. Independent school districts are included in the eligible applicant types.
Are colleges and universities eligible?
Yes. Eligible academic applicants include public and state-controlled institutions of higher education and private institutions of higher education.
Are nonprofit organizations eligible?
Yes. The announcement allows nonprofit organizations with 501(c)(3) IRS status and also nonprofit organizations without 501(c)(3) status (with the latter explicitly allowed when not an institution of higher education).
Are for-profit organizations eligible?
Yes. For-profit organizations are eligible, including small businesses and other for-profit entities (and the opportunity is not limited only to small businesses).
Are tribal governments and tribal organizations eligible?
Yes. The FOA includes Native American tribal governments (federally recognized) and Native American tribal organizations that are not federally recognized.
Are tribally controlled colleges and universities (TCCUs) eligible?
Yes. Tribally Controlled Colleges and Universities (TCCUs) are explicitly included.
Are HBCUs and other minority-serving institutions eligible?
Yes. The eligible categories listed include Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are included in the eligible applicant categories.
Are regional organizations eligible?
Yes. Regional organizations are listed as eligible applicants.
Are U.S. territories or possessions eligible?
Yes. The FOA includes U.S. territories or possessions among the eligible applicant categories.
Can non-U.S. (foreign) organizations apply?
Yes. The opportunity explicitly allows foreign organizations and foreign institutions to apply.
Are non-domestic components of U.S. organizations allowed to participate?
Yes. Non-domestic components of U.S. organizations are listed as eligible.
Are foreign components allowed under NIH policy?
Yes. The FOA states that foreign components (as defined by NIH policy) are allowed.
When was this funding opportunity posted?
The announcement was posted/created on November 14, 2014.
What was the application closing date?
The original and current closing date listed is February 23, 2015.
Is this funding opportunity still open?
No. The FOA has an archive date of March 26, 2015, indicating it is no longer an active open solicitation.
Where can the official NIH announcement be found?
The official announcement is hosted by NIH on grants.nih.gov at: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-066.html
Who is the contact for access or linking issues related to the FOA listing?
The contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
In one sentence, how should applicants think about the overall goal of this FOA?
Overall, it supports NIH-backed translational projects aiming to develop alternatives to traditional antibiotics that can help limit antibacterial resistance while moving toward practical therapeutic strategies for infected patients.
Browse more opportunities from the same category: Health
Next opportunity: Partnership On Climate Data And Information on Resilient Development
Previous opportunity: Rural Assistance Center for ORHP Cooperative Agreement
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 14 066
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 14 066) also looked into and applied for these:
| Funding Opportunity |
|---|
| Investigator Initiated Extended Clinical Trial (R01) Apply for PAR 15 040 Funding Number: PAR 15 040 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Diabetes and Cardiovascular Disease in Older Adults (R21) Apply for PA 15 038 Funding Number: PA 15 038 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Diabetes and Cardiovascular Disease in Older Adults (R01) Apply for PA 15 037 Funding Number: PA 15 037 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Diabetes and Cardiovascular Disease in Older Adults (R03) Apply for PA 15 039 Funding Number: PA 15 039 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Targeting Persistent HIV Reservoirs (TaPHIR) (R21/R33) Apply for PAR 15 041 Funding Number: PAR 15 041 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Administrative Supplements for Tobacco Regulatory Research on the Public Display of Harmful and Potentially Harmful Constituents (HPHC) Information (Admin Supp) Apply for PA 15 046 Funding Number: PA 15 046 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Family and Interpersonal Relationships in an Aging Context (R01) Apply for PA 15 042 Funding Number: PA 15 042 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Research Career Transition Award for Nurturing Clinician Investigators (K22) Apply for RFA DC 15 002 Funding Number: RFA DC 15 002 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Service Area Competition Additional Area (SAC AA) Dayton, OH Apply for HRSA 15 131 Funding Number: HRSA 15 131 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,104,448 |
| Local Capacity Initiative Program Apply for RFA 517 14 000006 Funding Number: RFA 517 14 000006 Agency: Dominican Republic USAID Santo Domingo Category: Health Funding Amount: $500,000 |
| Support for Orphans and Vulnerable Children in Nairobi and Coast Counties of Kenya Apply for RFA 615 14 000006 Funding Number: RFA 615 14 000006 Agency: Kenya USAID Nairobi Category: Health Funding Amount: $42,000,000 |
| Lab to Marketplace Tools for Biomedical and Behavioral Research (R43/R44) Apply for PA 15 052 Funding Number: PA 15 052 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Underactive Bladder in Aging (R03) Apply for PA 15 050 Funding Number: PA 15 050 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Underactive Bladder in Aging (R21) Apply for PA 15 051 Funding Number: PA 15 051 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| PPHF 2015 Preventive Health and Health Services Block Grants Behavioral Risk Factor Surveillance System (Pacific Jurisdictions) Financed in Part by 2015 Prevention and Public Health Funds Apply for CDC RFA DP15 1513 Funding Number: CDC RFA DP15 1513 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Alzheimers Disease Sequencing Project (ADSP) Replication Phase Analysis Studies (U01) Apply for RFA AG 16 002 Funding Number: RFA AG 16 002 Agency: National Institutes of Health Category: Health Funding Amount: $1,300,000 |
| NIA Coordinating Center for Genetics and Genomics of Alzheimers Disease (U54) Apply for RFA AG 16 001 Funding Number: RFA AG 16 001 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01) Apply for RFA HL 16 006 Funding Number: RFA HL 16 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Sickle Cell Disease Newborn Screening Program Apply for HRSA 15 078 Funding Number: HRSA 15 078 Agency: Health Resources and Services Administration Category: Health Funding Amount: $2,679,000 |
| Alcohol Education Project Grants (R25) Apply for PAR 15 054 Funding Number: PAR 15 054 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 14 066", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.